Type 2 diabetes mellitus
Conditions
Interventions
None listed
Sponsors
Hokkaido University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients with type 2 diabetes who have been taking Sulfonylurea, Glimepride(>=1 mg),Gliclazide (>=40 mg), Glibenclamide (>=1.25 mg) for more than 12 weeks, and are starting Ipragliflozine. 2)20 to 75 years old 3)BMI>=22 kg/m2 4)eGFR>=45 ml/min/1.73 m2 5)HbA1c 6.5 to 8.5 % 6)Written informed consent
Exclusion criteria
Exclusion criteria: 1)Hypersensitivity to Ipragliflozine 2)Uncontrolled diabetic retinopathy 3)Severe liver dysfunction,renal dysfunction,or heart failure 4)Pregnancy,nursing woman or possibly pregnant woman 5)Severe diabetic ketosis,diabetic coma 6)Severe infection,pre and post operation,severe trauma 7)Deficiency of insulin secretion (fasting CPR <0.5 ng/ml) 8) Patients who are inadequate to enter this study due to uncontrolled diet therapy or the other reasons by physician's judgments
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Frequency of hypoglycemia and glycemic control | — |
Secondary
| Measure | Time frame |
|---|---|
| Weight, BMI, Waist, Lipid metabolism, Blood pressure,Liver function, Complete blood count, renal function, electrolyte Dose and period of Sulfonylurea before clinical trial, Dose change of Sulfonylurea, Change of insulin dose (only patients using insulin) | — |
Countries
Japan
Contacts
Public ContactHideaki Miyoshi
Hokkaido University Hospital Department of Internal Medicine II
Outcome results
None listed